amifostine
Sign in to saveAmifostine (ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
Research
2,067 papers- Advances of Amifostine in Radiation Protection: Administration and Delivery.Molecular pharmaceutics · 2023
- Amifostine.Cancer biotherapy & radiopharmaceuticals · 1999
- Use of Amifostine for Cytoprotection during Radiation Therapy: A Review.Oncology · 2020
- Amifostine: the first selective-target and broad-spectrum radioprotector.The oncologist · 2007
- Amifostine and chemotherapy-related thrombocytopenia.Seminars in oncology · 1996
via PubMed
Article
6 sectionsContents
- Indications
- Pharmacokinetics
- Mechanism of action
- Adverse effects
- Contraindications
- References
Amifostine (ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
==Indications== Amifostine is used therapeutically to reduce the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents including alkylating agents (e.g. cyclophosphamide) and platinum-containing agents (e.g. cisplatin). It is also used to decrease the cumulative nephrotoxicity associated with platinum-containing agents. Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer.